Superinfections in COVID‐19 patients receiving extracorporeal membrane oxygenation support
Authors' conclusion
Bacteremia and VAP are common but does not seem to affect mortality, whereas pulmonary aspergillosis and CMV are associated with poor prognosis among COVID-19 patients treated with VV-ECMO.
Study context
- Population
- Patients with COVID-19 treated with veno-venous extracorporeal membrane oxygenation (VV-ECMO) >24 h at Rigshospitalet, Denmark, March 2020 to December 202166% male
- Participants
- 50 patients
- Outcome
- Superinfections and their association with mortality
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Superinfections detected
- Bacteremia
- 38%
- Ventilator associated pneumonia (VAP)
- 42%
- Invasive candidiasis
- 12%
- Pulmonary aspergillosis
- 12%
- Herpes simplex virus
- 14%
- Cytomegalovirus (CMV)
- 20%
Observational data: associations, not effects.
Further findings
Association of CMV with death
| OR (95% CI) | P value | ||
|---|---|---|---|
| CMVAdjusted for sex and age | 12.6 (1.9–257) | P = 0.05 | |
| 0.050.21520Odds ratio (log scale) |
- No associations between other superinfections and risk of death
- No patients with pulmonary aspergillosis survived
Discharged from hospital alive
- Discharged alive
- 42%
Time on VV-ECMO
- Median time on VV-ECMO, days (IQR 6.3-23.5)
- 14.5
Original publication
Superinfections in COVID‐19 patients receiving extracorporeal membrane oxygenation support. Acta Anaesthesiol Scand. Published 23 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →